156 results found.

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large Clinical Trial using GS-9973

Gilead Sciences - Recruiting 18 years or older.
- A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies.
GS-9973

Hematopoietic/Lymphoid Cancer, Non-hodgkin Lymphoma,B Cell, or Re Clinical Trial using Biological: anti-CD19-CAR vector-transduced T cells genetically engineered lymphocyte therapy

Chinese PLA General Hospital - Recruiting 50 years to 80 years.
- Anti-CD19 Chimeric Antigen Receptor Modified T Cells Infusion in Mantle Cell Lymphoma.
Biological: anti-CD19-CAR vector-transduced T cells genetically engineered lymphocyte therapy

Lymphoma, Non-Hodgkin Clinical Trial using BI 836826

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase I, Open-Label, Dose-Escalation Trial With BI 836826 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma of B Cell Origin.
BI 836826

Lymphoma Clinical Trial using Bendamustine; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone; PCI-32765 (Ibrutinib); Placebo

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL).
Bendamustine; Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone; PCI-32765 (Ibrutinib); Placebo

Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymph Clinical Trial using Idelalisib

Gilead Sciences - Recruiting 18 years or older.
- Single-agent CAL-101 for Previously Teated Low-grade Lymphoma: A Phase 1/2 Study of Safety, Efficacy, and Flow-cytometric Assessment of Tumor-cell Signaling Events.
Idelalisib

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using veliparib; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkins Lymphoma.
veliparib; cyclophosphamide; doxorubicin hydrochloride; laboratory biomarker analysis; pharmacological study

B-cell Childhood Acute Lymphoblastic Leukemia, Peripheral T-cell Clinical Trial using dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase 1 Study of Temsirolimus in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma.
dexamethasone; mitoxantrone hydrochloride; temsirolimus; vincristine sulfate; pegaspargase; methotrexate; laboratory biomarker analysis; pharmacological study

Non-Hodgkin's Lymphoma Clinical Trial using bendamustine; RO5072759

Genentech - Recruiting 18 years or older.
- An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma.
bendamustine; RO5072759

Lymphocytic Leukemia, Chronic, Lymphoma, B-Cell Clinical Trial using GDC-0853

Genentech - Recruiting 18 years or older.
- AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0853 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA.
GDC-0853

Non-Hodgkin's Lymphoma, Solid Cancers Clinical Trial using GDC-0980

Genentech - Recruiting 18 years or older.
- An Open-label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors and Non-Hodgkin's Lymphoma.
GDC-0980

Lymphoma, B-Cell, Non-Hodgkin's Lymphoma Clinical Trial using DCDS4501A; rituximab [MabThera/Rituxan]; cyclophosphamide; prednisone; doxorubicin

Genentech - Recruiting 60 years to 80 years.
- A PHASE Ib STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF DCDS4501A IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA.
DCDS4501A; rituximab [MabThera/Rituxan]; cyclophosphamide; prednisone; doxorubicin

Hodgkin's Lymphoma Clinical Trial using Panobinostat; Ifosfamide; Mesna; Carboplatin; Etoposide; Pegfilgrastim

M.D. Anderson Cancer Center - Recruiting 16 years or older.
- Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by a Randomized Phase-II Study of ICE Compared With Panobinostat Plus ICE for Patients With Relapsed and Refractory Classical Hodgkin Lymphoma.
Panobinostat; Ifosfamide; Mesna; Carboplatin; Etoposide; Pegfilgrastim

Non-Hodgkin's Lymphoma, Multiple, Mycosis Fungoides, Hodgkin's Ly Clinical Trial using Dasatinib

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies..
Dasatinib

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Mul Clinical Trial using Dasatinib; laboratory biomarker analysis

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years or older.
- Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies..
Dasatinib; laboratory biomarker analysis

CD20+, B-cell Lymphomas, Mantle Cell Lymphoma, Non-Mantle Cell Lo Clinical Trial using Everolimus and Rituximab

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas and Hodgkin's Lymphoma.
Everolimus and Rituximab

Lymphoma Clinical Trial using Ofatumumab; Ifosfamide; Etoposide; Mesna; G-CSF; Stem Cell Collection

M.D. Anderson Cancer Center - Recruiting 18 years to 70 years.
- Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas.
Ofatumumab; Ifosfamide; Etoposide; Mesna; G-CSF; Stem Cell Collection

Lymphoma, Non-Hodgkin Clinical Trial using Copanlisib (BAY80-6946)

Bayer - Recruiting 18 years or older.
- Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas.
Copanlisib (BAY80-6946)

Lymphoma, Non-Hodgkin Clinical Trial using Rituximab; Lenalidomide; Placebo

Celgene Corporation - Recruiting 18 years or older.
- A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma (The 'AUGMENT' Study).
Rituximab; Lenalidomide; Placebo

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Pre Clinical Trial using brentuximab vedotin; doxorubicin hydrochloride; vinblastine; dacarbazine; quality-of-life assessment; DNA analysis; RNA analysis; fludeoxyglucose F 18; positron emission tomography; laboratory biomarker analysis; immunohistochemistry staining method; polymorphism analysis

Northwestern University - Recruiting 60 years or older.
- A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma.
brentuximab vedotin; doxorubicin hydrochloride; vinblastine; dacarbazine; quality-of-life assessment; DNA analysis; RNA analysis; fludeoxyglucose F 18; positron emission tomography; laboratory biomarker analysis; immunohistochemistry staining method; polymorphism analysis

B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or W Clinical Trial using AVL-292

Celgene Corporation - Recruiting 18 years or older.
- Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia.
AVL-292

T Cell Non-Hodgkin Lymphoma Clinical Trial using High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin

Memorial Sloan-Kettering Cancer Center - Recruiting 16 years or older.
- A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma.
High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin

Non-Hodgkin's Lymphoma Clinical Trial using ABT-199; Ketoconazole

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199.
ABT-199; Ketoconazole

Non-Hodgkin's Lymphoma Clinical Trial using ABT-199; Rifampin

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study to Assess the Effect of Rifampin on the Pharmacokinetics of ABT-199.
ABT-199; Rifampin

Lymphoma, Non-Hodgkin Clinical Trial using Ribomustin; rituximab

Astellas Pharma Inc - Recruiting 18 years or older.
- Observational Program for Evaluation of Ribomustin and Rituximab Combined Therapy With Following Rituximab Maintenance of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma.
Ribomustin; rituximab

Non-Hodgkin's Lymphoma Clinical Trial using RO5072759; rituximab [MabThera/Rituxan]; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multicentre, Phase III, Open Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) + Chemotherapy Compared to Rituximab + Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders..
RO5072759; rituximab [MabThera/Rituxan]; chemotherapy

Non-Hodgkin's Lymphoma Clinical Trial using Mabthera intravenous; MabThera subcutaneous

Hoffmann-La Roche - Recruiting 18 years or older.
- A Two-stage Phase III, International, Multi-center, Randomized, Controlled, Open-label Study to Investigate the Pharmacokinetics, Efficacy and Safety of Rituximab SC in Combination With CHOP or CVP Versus Rituximab IV in Combination With CHOP or CVP in Patients With Previously Untreated Follicular Lymphoma Followed by Maintenance Treatment With Either Rituximab SC or Rituximab IV.
Mabthera intravenous; MabThera subcutaneous

Non-Hodgkin's Lymphoma Clinical Trial using rituximab [MabThera/Rituxan]; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- .
rituximab [MabThera/Rituxan]; chemotherapy

Lymphoma, B-Cell, Non-Hodgkin's Lymphoma Clinical Trial using rituximab [MabThera/Rituxan]; CHOP; CVP; bendamustine

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- A Randomized, Open-label, Multicenter Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a.
rituximab [MabThera/Rituxan]; CHOP; CVP; bendamustine

Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Clinical Trial using Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Gilead Sciences - Recruiting 18 years or older.
- A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
Idelalisib; Rituximab; Bendamustine; Ofatumumab; Fludarabine; Everolimus; Bortezomib; Chlorambucil; Lenalidomide

Non-Hodgkin Lymphoma Clinical Trial using Bendamustine hydrochloride

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- An Open-Label Study to Evaluate Bendamustine Hydrochloride in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma (NHL) Refractory to Rituximab Treatment.
Bendamustine hydrochloride

Graft Versus Host Disease, Leukemia, or Lymphoma Clinical Trial using rituximab; fludarabine phosphate; melphalan; sirolimus; tacrolimus; allogeneic hematopoietic stem cell transplantation; indium In 111 ibritumomab tiuxetan; yttrium Y 90 ibritumomab tiuxetan; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years to 69 years.
- A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan.
rituximab; fludarabine phosphate; melphalan; sirolimus; tacrolimus; allogeneic hematopoietic stem cell transplantation; indium In 111 ibritumomab tiuxetan; yttrium Y 90 ibritumomab tiuxetan; laboratory biomarker analysis

Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Mac Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies.
CB-839

Lymphoma, or Nonneoplastic Condition Clinical Trial using bleomycin sulfate; filgrastim; ABVD regimen; BEACOPP regimen; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide; prednisone; procarbazine hydrochloride; vinblastine sulfate; vincristine sulfate

Southwest Oncology Group - Recruiting 18 years to 60 years.
- A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging.
bleomycin sulfate; filgrastim; ABVD regimen; BEACOPP regimen; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide; prednisone; procarbazine hydrochloride; vinblastine sulfate; vincristine sulfate

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using indium In 111 anti-CD45 monoclonal antibody BC8; yttrium Y 90 anti-CD45 monoclonal antibody BC8; peripheral blood stem cell transplantation

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies.
indium In 111 anti-CD45 monoclonal antibody BC8; yttrium Y 90 anti-CD45 monoclonal antibody BC8; peripheral blood stem cell transplantation

Recurrent Adult Hodgkin Lymphoma Clinical Trial using temsirolimus; brentuximab vedotin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Brentuximab Vedotin in Combination With Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma.
temsirolimus; brentuximab vedotin; laboratory biomarker analysis

Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disea Clinical Trial using Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 74 years.
- Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders.
Cyclophosphamide; rituximab; Methotrexate; Sirolimus; Cyclosporine; Doxorubicin hydrochloride; Etoposide; Fludarabine phosphate; Prednisone; Vincristine sulfate; Cytarabine; Tacrolimus; Alemtuzumab

Renal Cell Carcinoma, Breast Cancer, Colon Cancer, Lung Cancer, o Clinical Trial using dimethane sulfonate (DMS612, NSC 281612)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase 1, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies.
dimethane sulfonate (DMS612, NSC 281612)

Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed F Clinical Trial using Pixantrone + Rituximab; Gemcitabine + Rituximab

Cell Therapeutics - Recruiting 18 years or older.
- A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant.
Pixantrone + Rituximab; Gemcitabine + Rituximab

Non Hodgkin's Lymphoma Clinical Trial using filgrastim; Rituximab

National Institutes of Health Clinical Center (CC) - Recruiting 12 years or older.
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma.
filgrastim; Rituximab

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphom Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol.

Hodgkin Disease, or Hodgkin Lymphoma Clinical Trial using Filgrastim; Plerixafor; Yttrium-Daclizumab (CHX-A Daclizumab); Carmustine; Etoposide; Cytarabine; Melphalan; Ca(2+)-DTPA

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase I/II Trial of Yttrium-90-labeled Daclizumab (Anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin s Lymphoma.
Filgrastim; Plerixafor; Yttrium-Daclizumab (CHX-A Daclizumab); Carmustine; Etoposide; Cytarabine; Melphalan; Ca(2+)-DTPA

Non-Hodgkin Lymphoma, Multiple Myleoma, Chronic Lympocytic Leukem Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 79 years.
- A Multi-Center International Hospital-Based Case-Control Study of Lymphoma in Asia (AsiaLymph).

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies.
yttrium Y 90 anti-CD45 monoclonal antibody BC8; carmustine; etoposide; cytarabine; melphalan; peripheral blood stem cell transplantation; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Non-Hodgkin's Lymphoma, or Active Solid Malignancy Clinical Trial using PET Imaging using 124 IPUH71

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 90 years.
- PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study.
PET Imaging using 124 IPUH71

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphob Clinical Trial using Clofarabine; Mitoxantrone

New York Medical College - Recruiting N/A to 30 years.
- A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma.
Clofarabine; Mitoxantrone

Lymphoma, Non Hodgkin Clinical Trial using rituximab [MabThera/Rituxan]

Hoffmann-La Roche - Recruiting 18 years to 80 years.
- OPEN LABEL, SINGLE-ARM, PHASE IIIb CLINICAL TRIAL TO EVALUATE THE SAFETY OF SWITCHING FROM INTRAVENOUS RITUXIMAB TO SUBCUTANEOUS RITUXIMAB DURING FIRST LINE TREATMENT FOR CD20+ NON-HODGKIN'S FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA..
rituximab [MabThera/Rituxan]

Hodgkin Lymphoma, Non-Hodgkin Lymphoma, or Hodgkin Disease Clinical Trial using Antigen Escalation Stage; Dose escalation study of T cells

Baylor College of Medicine - Recruiting N/A or older.
- Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma.
Antigen Escalation Stage; Dose escalation study of T cells

Hodgkin's Disease, Non-Hodgkin's Lymphoma, Lymphoproliferative Di Clinical Trial using LMP, BARF1 & EBNA1 specific CTLs: A; LMP, BARF1 & EBNA1 specific CTLs : B

Baylor College of Medicine - Recruiting N/A or older.
- Administration of Rapidly Generated LMP, BARF1 And EBNA1 Specific Cytotoxic T-Lymphocytes To Patients With EBV-Positive Lymphoma.
LMP, BARF1 & EBNA1 specific CTLs: A; LMP, BARF1 & EBNA1 specific CTLs : B

Hematopoietic/Lymphoid Cancer Clinical Trial using brentuximab vedotin; laboratory biomarker analysis; pharmacological study

Fred Hutchinson Cancer Research Center - Recruiting 12 years to 75 years.
- Maintenance Therapy With Brentuximab Vedotin (SGN-35) After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma and CD30+ Hematologic Malignancies.
brentuximab vedotin; laboratory biomarker analysis; pharmacological study

Follicular Non-Hodgkin's Lymphoma Clinical Trial using R-CHOP; Observation; Maintenance weekly x4; Ibritumomab Tiuxetan + Maintenance; Standard Maintenance

Fondazione Italiana Linfomi ONLUS - Recruiting 18 years or older.
- A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma..
R-CHOP; Observation; Maintenance weekly x4; Ibritumomab Tiuxetan + Maintenance; Standard Maintenance

Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Clinical Trial using clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

St. Jude Children's Research Hospital - Recruiting N/A to 21 years.
- T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant.
clofarabine; cytarabine; busulfan; Plerixafor; cyclophosphamide; antithymocyte globulin (rabbit); stem cells; Tacrolimus; mycophenolate mofetil

Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Bone Marro Clinical Trial using anti-thymocyte globulin; cyclosporine

Stanford University - Recruiting 18 years or older.
- A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma.
anti-thymocyte globulin; cyclosporine

Lymphoma, Non-Hodgkin, or Hodgkin's Disease Clinical Trial

Stanford University - Recruiting 18 years or older.
- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease.

Non-Hodgkin's Lymphoma (NHL) Clinical Trial using temsirolimus

Pfizer - Recruiting 18 years or older.
- A Randomized Phase 4 Study Comparing 2 Doses Of Intravenous Temsirolimus In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL).
temsirolimus

Lymphoma, B-Cell Clinical Trial using inotuzumab ozogamicin

Pfizer - Recruiting 18 years or older.
- A Phase 1/2 Study Of CMC-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-Cell Non-Hodgkin's Lymphoma.
inotuzumab ozogamicin

Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML); Clinical Trial using CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Columbia University - Recruiting N/A to 22 years.
- CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease.
CliniMACS CD34+ Reagent System; Thiotepa; Cyclophosphamide; Alemtuzumab; Tacrolimus; Melphalan; Busulfan; Fludarabine

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymph Clinical Trial using Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital - Recruiting 18 years to 70 years.
- Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Haploidentical Bone Marrow/Kidney

Lymphoma Clinical Trial using cyclophosphamide; cyclosporine; fludarabine phosphate; gemcitabine hydrochloride; ifosfamide; mechlorethamine hydrochloride; melphalan; methotrexate; mycophenolate mofetil; prednisone; procarbazine hydrochloride; vincristine sulfate; vinorelbine tartrate; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; umbilical cord blood transplantation; total-body irradiation

Memorial Sloan-Kettering Cancer Center - Recruiting 13 years to 65 years.
- An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma.
cyclophosphamide; cyclosporine; fludarabine phosphate; gemcitabine hydrochloride; ifosfamide; mechlorethamine hydrochloride; melphalan; methotrexate; mycophenolate mofetil; prednisone; procarbazine hydrochloride; vincristine sulfate; vinorelbine tartrate; allogeneic bone marrow transplantation; allogeneic hematopoietic stem cell transplantation; nonmyeloablative allogeneic hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; umbilical cord blood transplantation; total-body irradiation

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosi Clinical Trial using carfilzomib; romidepsin; laboratory biomarker analysis

Northwestern University - Recruiting 18 years or older.
- A Randomized Phase I Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma.
carfilzomib; romidepsin; laboratory biomarker analysis

Lymphoma, Non-Hodgkin Clinical Trial using PF-05082566; rituximab

Pfizer - Recruiting 18 years or older.
- A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL).
PF-05082566; rituximab

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using ipilimumab; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma.
ipilimumab; rituximab; laboratory biomarker analysis

Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Clinical Trial using plerixafor; filgrastim; etoposide; leukapheresis

Case Comprehensive Cancer Center - Recruiting 18 years to 78 years.
- A Study of Hematopoietic Stem Cell Supermobilization in Patients With Non-Hodgkin Lymphoma.
plerixafor; filgrastim; etoposide; leukapheresis

Lymphoma, or Hodgkin Disease Clinical Trial using tumor tissue aspiration; phlebotomy

Stanford University - Recruiting N/A to 21 years.
- Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy.
tumor tissue aspiration; phlebotomy

Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Clinical Trial using brentuximab vedotin; etoposide; prednisone; doxorubicin; cyclophosphamide; Dacarbazine(R); filgrastim; quality of life assessment; radiation therapy

St. Jude Children's Research Hospital - Recruiting N/A to 18 years.
- Adcetris Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Low Dose Tailored-Field Radiation Therapy for Unfavorable Risk Pediatric Hodgkin Lymphoma.
brentuximab vedotin; etoposide; prednisone; doxorubicin; cyclophosphamide; Dacarbazine(R); filgrastim; quality of life assessment; radiation therapy

B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Diffuse Clinical Trial using rituximab; prednisone; etoposide; doxorubicin hydrochloride; cytarabine; vincristine sulfate; cyclophosphamide; methotrexate; methylprednisolone; leucovorin calcium; therapeutic hydrocortisone

Children's Oncology Group - Recruiting N/A to 18 years.
- Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients.
rituximab; prednisone; etoposide; doxorubicin hydrochloride; cytarabine; vincristine sulfate; cyclophosphamide; methotrexate; methylprednisolone; leucovorin calcium; therapeutic hydrocortisone

Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer Clinical Trial

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individual With Cancer.

Non-Hodgkin's Lymphoma Clinical Trial using Bendamustine; Ofatumumab; Carboplatin; Etoposide; CT Scan; PET Scan; Stem Cell Transplant (STC)

Thomas Jefferson University - Recruiting 18 years or older.
- Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas.
Bendamustine; Ofatumumab; Carboplatin; Etoposide; CT Scan; PET Scan; Stem Cell Transplant (STC)

Indolent Non-Hodgkin's Lymphoma Clinical Trial using Arm A: Rituximab; Arm B: GA101

PrECOG, LLC. - Recruiting 18 years or older.
- Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma.
Arm A: Rituximab; Arm B: GA101

B-cell Non-Hodgkin Lymphoma Clinical Trial using 0.5 mg/m2 DI-Leu16-IL2; 1.0 mg/m2 DI-Leu16-IL2; 2.0 mg/m2 DI-Leu16-IL2; 4.0 mg/m2 DI-Leu16-IL2; 6.0 mg/m2 DI-Leu16-IL2; 8.0 mg/m2 DI-Leu16-IL2; 10.0 mg/m2 DI-Leu16-IL2

Alopexx Oncology, LLC - Recruiting 18 years or older.
- A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL).
0.5 mg/m2 DI-Leu16-IL2; 1.0 mg/m2 DI-Leu16-IL2; 2.0 mg/m2 DI-Leu16-IL2; 4.0 mg/m2 DI-Leu16-IL2; 6.0 mg/m2 DI-Leu16-IL2; 8.0 mg/m2 DI-Leu16-IL2; 10.0 mg/m2 DI-Leu16-IL2

Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma, Clinical Trial using rituximab

Biocad - Recruiting 18 years to 95 years.
- A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma.
rituximab

B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Clinical Trial using alisertib; romidepsin; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas.
alisertib; romidepsin; laboratory biomarker analysis

T-cell Non-Hodgkin Lymphoma Clinical Trial using Cyclophosphamide; Doxorubicin; Vincristine; Etoposide; Prednisone; Filgrastim; Plerixafor; Stem Cell Collection; Palifermin; Gemcitabine; Busulfan; Melphalan; Stem Cell Transplant

Dana-Farber Cancer Institute - Recruiting 18 years to 70 years.
- A Phase II Study of CHOEP Induction Followed by Gemcitabine/Busulfan/Melphalan Autologous Stem Cell Transplantation for Patients With Newly Diagnosed T-Cell Lymphoma.
Cyclophosphamide; Doxorubicin; Vincristine; Etoposide; Prednisone; Filgrastim; Plerixafor; Stem Cell Collection; Palifermin; Gemcitabine; Busulfan; Melphalan; Stem Cell Transplant

Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission, Clinical Trial using POL6326; Leukapheresis; PBSC Transplant

Polyphor Ltd. - Recruiting 18 years to 75 years.
- A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies.
POL6326; Leukapheresis; PBSC Transplant

Lymphoma, Non-Hodgkin's Clinical Trial using PNT2258

Pronai Therapeutics, Inc - Recruiting 18 years or older.
- PNT2258-02: A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma.
PNT2258

Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma Clinical Trial using Urelumab (BMS-663513)

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL).
Urelumab (BMS-663513)

Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, or Chronic L Clinical Trial using SAR245409

Sanofi - Recruiting 18 years or older.
- A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia.
SAR245409

Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, or Non-Hodg Clinical Trial using Palifermin; Lupron; without the addition of palifermin or Lupron; peripheral blood stem cell transplantation

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 60 years.
- An Open Label Randomized Phase II Study of Palifermin With or Without Leuprolide Acetate Versus Control for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation.
Palifermin; Lupron; without the addition of palifermin or Lupron; peripheral blood stem cell transplantation

Indolent Non-Hodgkin Lymphoma Clinical Trial using IPI-145

Infinity Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO).
IPI-145

Solid Tumors and Non-Hodgkin's Lymphoma Clinical Trial using LY2780301; Gemcitabine

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- A Phase Ib, Open-label, Dose Escalation Study of the Safety, Tolerability and Efficacy of LY2780301 (a p70/AKT Inhibitor) in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer.
LY2780301; Gemcitabine

Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non Clinical Trial using autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 18 years or older.
- Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma.
autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Diffuse Clinical Trial using doxorubicin hydrochloride; vincristine sulfate; vorinostat; prednisone; rituximab; cyclophosphamide; etoposide; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-cell Non-Hodgkin's Lymphoma.
doxorubicin hydrochloride; vincristine sulfate; vorinostat; prednisone; rituximab; cyclophosphamide; etoposide; laboratory biomarker analysis; pharmacological study

Recurrent Adult Hodgkin Lymphoma, or Recurrent/Refractory Childho Clinical Trial using brentuximab vedotin; gemcitabine hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 13 Months to 30 years.
- A Phase 1/2 Study of Brentuximab Vedotin (SGN35, IND# 117117) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma.
brentuximab vedotin; gemcitabine hydrochloride; laboratory biomarker analysis

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of the Aurora Kinase A Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies.
alisertib; vorinostat; laboratory biomarker analysis; pharmacological study

Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma Clinical Trial using Nivolumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS-936558) in Subjects With Relapsed or Refractory Hematologic Malignancy.
Nivolumab

Solid Tumors, or Lymphoma Clinical Trial using PU-H71

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma.
PU-H71

Non-Hodgkin's Lymphoma (NHL) Clinical Trial using [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

Bayer - Recruiting N/A or older.
- Drug Use Investigation of Zevalin.
[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

NHL Subjects Who Have Failed Prior Systemic Therapy Clinical Trial using ADI-PEG 20

Polaris Group - Recruiting 20 years or older.
- Phase 2 Study of ADI PEG 20 in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy.
ADI-PEG 20

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lym Clinical Trial using alisertib; bortezomib; rituximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma.
alisertib; bortezomib; rituximab; laboratory biomarker analysis

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using romidepsin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction.
romidepsin; pharmacological study

Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymph Clinical Trial using bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

Barbara Ann Karmanos Cancer Institute - Recruiting 18 years to 70 years.
- A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.
bortezomib; filgrastim; autologous hematopoietic stem cell transplantation

MDS (Myelodysplastic Syndrome), Myeloproliferative Disorder, Lymp Clinical Trial using Graft Manipulation (CD34+ Selection)

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 80 years.
- Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies.
Graft Manipulation (CD34+ Selection)

Lymphoma, Non-Hodgkin, or Hodgkin Disease Clinical Trial using Abraxane

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase I/II Institutional Study of Abraxane in Recurrent and Refractory Lymphoma.
Abraxane

Leukemia, or Lymphoma Clinical Trial using valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL.
valproic acid; western blotting; laboratory biomarker analysis; pharmacological study

Lymphoma Clinical Trial using autologous immunoglobulin idiotype-KLH conjugate vaccine; rituximab; sargramostim

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of Maintenance Rituximab Plus FavIdr and GM-CSF Immunotherapy in Patients With Treatment-Naive Indolent B-Cell Lymphoma.
autologous immunoglobulin idiotype-KLH conjugate vaccine; rituximab; sargramostim

Follicular Lymphoma, B-cell Lymphoma, or Non-Hodgkin's Lymphoma Clinical Trial using Ibrutinib; rituximab

Pharmacyclics - Recruiting 18 years or older.
- A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma.
Ibrutinib; rituximab

Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic M Clinical Trial using iTreg

Masonic Cancer Center, University of Minnesota - Recruiting 18 years to 75 years.
- Dose Escalation Study With Extension of Inducible Regulatory T Cells (iTregs) in Adult Patients Undergoing Non-Myeloablative HLA Identical Sibling Donor Peripheral Blood Stem Cell Transplantation.
iTreg

Non-Hodgkin's Lymphoma Clinical Trial using ABT-199; Bendamustine; Rituximab

AbbVie - Recruiting 18 years or older.
- A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma.
ABT-199; Bendamustine; Rituximab

Hodgkin Lymphoma Clinical Trial using brentuximab vedotin; doxorubicin; bleomycin; vinblastine; dacarbazine

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma.
brentuximab vedotin; doxorubicin; bleomycin; vinblastine; dacarbazine

Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage Clinical Trial using ofatumumab; bendamustine hydrochloride; bortezomib; laboratory biomarker analysis; positron emission tomography with radiolabeled targeting agents; fludeoxyglucose F 18

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma.
ofatumumab; bendamustine hydrochloride; bortezomib; laboratory biomarker analysis; positron emission tomography with radiolabeled targeting agents; fludeoxyglucose F 18

Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma Clinical Trial using Busulfan; Fludarabine

West Virginia University - Recruiting 18 years to 70 years.
- Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II Study.
Busulfan; Fludarabine

Multiple Myeloma, Myelodysplastic Syndrome, Hodgkin's Lymphoma, o Clinical Trial using MK-3475

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects With Hematologic Malignancies.
MK-3475

Hodgkin Lymphoma, or Metastatic Breast Cancer Clinical Trial

Rennes University Hospital - Recruiting 18 years to 75 years.
- BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology.

Non-Hodgkin's Lymphoma Clinical Trial using Carmustine; Etoposide; Cytarabine; Melphalan; Pegfilgrastim; 19-28z T CELLS; Autologous Stem Cell Transplantation

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma.
Carmustine; Etoposide; Cytarabine; Melphalan; Pegfilgrastim; 19-28z T CELLS; Autologous Stem Cell Transplantation

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Cutaneou Clinical Trial using O6-benzylguanine; carmustine; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 19 years or older.
- Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma.
O6-benzylguanine; carmustine; laboratory biomarker analysis

Lymphoma, Non-Hodgkin Clinical Trial using Stem cell infusion; TLI; Anti-thymocyte globulin; Solumedrol; Tacrolimus; Mycophenolate mofetil

Washington University School of Medicine - Recruiting 18 years to 70 years.
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma.
Stem cell infusion; TLI; Anti-thymocyte globulin; Solumedrol; Tacrolimus; Mycophenolate mofetil

Non Hodgkin's Lymphoma, NHL, Aggressive NHL, or Diffuse Large B-c Clinical Trial using Veltuzumab and 90Y-Epratuzumab Tetraxetan; 90Y-epratuzumab tetraxetan; veltuzumab

Immunomedics, Inc. - Recruiting 18 years or older.
- Phase I/II Study of Veltuzumab Combined With 90Y-Epratuzumab Tetraxetan in Patients With Relapsed/Refractory, Aggressive Non- Hodgkin's Lymphoma.
Veltuzumab and 90Y-Epratuzumab Tetraxetan; 90Y-epratuzumab tetraxetan; veltuzumab

Hodgkin Lymphoma Clinical Trial using Brentuximab vedotin (SGN-35); Doxorubicin HCL; Vinblastine Sulfate; Dacarbazine; Involved-Site Radiation Therapy (ISRT); Interim PET

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 60 years.
- A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy and 30 Gray Involved-Site Radiotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma.
Brentuximab vedotin (SGN-35); Doxorubicin HCL; Vinblastine Sulfate; Dacarbazine; Involved-Site Radiation Therapy (ISRT); Interim PET

Hodgkin Lymphoma, or Diffuse Large B-Cell Lymphoma Clinical Trial using Cylcophosphamide; Etoposide; Alemtuzumab; Doxorubicin; Prednisone; Filgrastim; Rituximab; Vincristine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas.
Cylcophosphamide; Etoposide; Alemtuzumab; Doxorubicin; Prednisone; Filgrastim; Rituximab; Vincristine

B-cell Non Hodgkin Lymphoma, or Mature B-cell Leukemia Burkitt-ty Clinical Trial using Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C; Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 6 Months to 17 years.
- Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial.
Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C; Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C

Hodgkin Lymphoma, or Anaplastic Large Cell Lymphoma Clinical Trial using Adcetris; Bendamustine

Columbia University - Recruiting 18 years or older.
- A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma.
Adcetris; Bendamustine

Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma Clinical Trial using CAT-8015 (Moxetumomab Pasudotox)

MedImmune LLC - Recruiting 6 Months to 25 years.
- A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin's Lymphoma (NHL).
CAT-8015 (Moxetumomab Pasudotox)

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using iodine I 131 monoclonal antibody BC8; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Study Evaluating Escalating Doses of 131I-BC8 (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies.
iodine I 131 monoclonal antibody BC8; autologous hematopoietic stem cell transplantation; laboratory biomarker analysis

Non-Hodgkin's Lymphoma Clinical Trial using ibritumomab tiuxetan; BEAM chemotherapy and autologous stem-cell transplantation

Sheba Medical Center - Recruiting 18 years to 70 years.
- SPINOZA / ???????. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma.
ibritumomab tiuxetan; BEAM chemotherapy and autologous stem-cell transplantation

B Cell Lymphoma, or Chronic Lymphocytic Leukemia Clinical Trial using CD19CAR-28-zeta T cells; Ipilimumab

Baylor College of Medicine - Recruiting N/A or older.
- Phase I Study Of CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, Acute Lymphocytic Leukemia, and Chronic Lymphocytic Leukemia.
CD19CAR-28-zeta T cells; Ipilimumab

Non-Hodgkin's Lymphoma Clinical Trial using Bendamustine + Rituximab + Pixantrone

Duke University - Recruiting 18 years or older.
- Phase I/II Study of the Combination of Bendamustine, Rituximab and Pixantrone in Patients With Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma.
Bendamustine + Rituximab + Pixantrone

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Clinical Trial using alisertib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma.
alisertib; pharmacological study; laboratory biomarker analysis

Lymphoma Clinical Trial using alemtuzumab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate; flow cytometry; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study.
alemtuzumab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate; flow cytometry; pharmacological study

Hodgkin's Disease, or Non-Hodgkin's Lymphoma Clinical Trial using Vorinostat (SAHA) and Niacinamide; Vorinostat, Niacinamide and Etoposide

Columbia University - Recruiting 18 years or older.
- Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies.
Vorinostat (SAHA) and Niacinamide; Vorinostat, Niacinamide and Etoposide

Lymphoma Clinical Trial using rituximab

National Cancer Institute (NCI) - Recruiting 18 years or older.
- An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma.
rituximab

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Pre Clinical Trial using panobinostat; lenalidomide

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma.
panobinostat; lenalidomide

Lymphoma Clinical Trial using carmustine; cyclophosphamide; etoposide; peripheral blood stem cell transplantation; irradiation therapy; G-CSF; Cytarabine

Masonic Cancer Center, University of Minnesota - Recruiting N/A to 75 years.
- Autologous Peripheral Blood Stem Cell Transplant for Patients With Lymphoma.
carmustine; cyclophosphamide; etoposide; peripheral blood stem cell transplantation; irradiation therapy; G-CSF; Cytarabine

Hodgkin Disease Clinical Trial using Lenalidomide

Washington University School of Medicine - Recruiting 18 years or older.
- A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma.
Lenalidomide

Hodgkin Lymphoma Clinical Trial using ABVD + FDG-PET/CT Scan treatment adaptation; BEACOPPesc

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years to 60 years.
- Very Early FDG-PET/CT-response Adapted Therapy for Advanced Stage Hodgkin Lymphoma, a Randomized Phase III Non-inferiority Study of the EORTC Lymphoma Group.
ABVD + FDG-PET/CT Scan treatment adaptation; BEACOPPesc

Solid Tumors, or Non-Hodgkin's Lymphoma Clinical Trial using Efavirenz

Institut Bergoni‚ - Recruiting 18 years to 80 years.
- Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure..
Efavirenz

Lymphoma Clinical Trial using Lenalidomide; Rituximab

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma.
Lenalidomide; Rituximab

Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Fo Clinical Trial using PI3K inhibitor BKM120; laboratory biomarker analysis

Mayo Clinic - Recruiting 18 years or older.
- A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma.
PI3K inhibitor BKM120; laboratory biomarker analysis

Non-Hodgkin Lymphoma Clinical Trial using Betalutin

Nordic Nanovector - Recruiting 18 years or older.
- A Phase I/II Study of 177Lu-HH1 (Betalutin)Radioimmunotherapy for Treatment of Relapsed CD37+ Non-Hodgkin Lymphoma.
Betalutin

Hodgkin Lymphoma Clinical Trial using ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine); 20 Gy IFRT (Involved Field Radiotherapy)

University of Cologne - Recruiting 18 years to 75 years.
- HD16 for Early Stages - Treatment Optimization Trial in the First-line Treatment of Early Stage Hodgkin Lymphoma; Treatment Stratification by Means of FDG-PET.
ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine); 20 Gy IFRT (Involved Field Radiotherapy)

Hodgkin Lymphoma Clinical Trial using BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone); ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine); 30Gy IF-RT (Involved-Field Radiotherapy); 30Gy IN-RT (Involved-Node Radiotherapy)

University of Cologne - Recruiting 18 years to 60 years.
- HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma.
BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone); ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine); 30Gy IF-RT (Involved-Field Radiotherapy); 30Gy IN-RT (Involved-Node Radiotherapy)

Lymphoma Clinical Trial using biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting N/A or older.
- Hodgkin Disease (HD) Banking Study.
biologic sample preservation procedure

Leukemia, or Lymphoma Clinical Trial using biologic sample preservation procedure

National Cancer Institute (NCI) - Recruiting N/A to 30 years.
- A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens.
biologic sample preservation procedure

Hodgkin's Lymphoma Clinical Trial using Temsirolimus

Loyola University - Recruiting 18 years or older.
- Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma.
Temsirolimus

Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopeni Clinical Trial using Eltrombopag Olamine

Fondazione Progetto Ematologia - Recruiting 18 years or older.
- Open Label Multicenter Study of Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs).
Eltrombopag Olamine

B-Cell Lymphomas Clinical Trial using Ofatumumab

Grupo Espa¤ol de Linfomas y Transplante Aut¢logo de M‚dula Osea - Recruiting 18 years to 65 years.
- Ofatumumab as Part of the Reduced Intensity Conditioning Regimen (RIC) for Patients With High Risk B Non Hodgkin's Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation.
Ofatumumab

Lymphoma, Lymphoma, Non-Hodgkin, or Large B Cell Diffuse Lymphoma Clinical Trial using FLT-PET/CT; FDG-PET/CT; FLT

Stanford University - Recruiting N/A or older.
- FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma.
FLT-PET/CT; FDG-PET/CT; FLT

T-cell Lymphoma Clinical Trial using Lenalidomide

AHS Cancer Control Alberta - Recruiting 18 years or older.
- A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma.
Lenalidomide

Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, or Non- Clinical Trial using Fenretinide; Cytarabine; Methotrexate

South Plains Oncology Consortium - Recruiting N/A to 21 years.
- A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children With Recurrent or Resistant Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), and Non-Hodgkin's Lymphoma (NHL) IND #70,058'.
Fenretinide; Cytarabine; Methotrexate

Hodgkin's Lymphoma Clinical Trial

Ospedale Santa Croce-Carle Cuneo - Recruiting 18 years to 60 years.
- Dual Point Acquisition in the Interim Pet Scan Performed During ABVD Treatment, in Early-Stage Hodgkin's Lymphoma Patients With Bulky Lesions.

Hodgkin Lymphoma Clinical Trial using Rituximab; Involved field irradiation

Fondazione Michelangelo - Recruiting 18 years or older.
- Phase III Study Comparing Rituximab-supplemented ABVD (R-ABVD) With ABVD Followed by Involved-field Radiotherapy (ABVD-RT) in Limited Stage (Stage I-IIA With no Areas of Bulk) Hodgkin's Lymphoma.
Rituximab; Involved field irradiation

Hodgkin Disease, or Lymphoma, Non-Hodgkin Clinical Trial using Database

King Faisal Specialist Hospital & Research Center - Recruiting 14 years to 85 years.
- Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases.
Database

HIV-associated Hodgkin Lymphoma Clinical Trial using Doxorubicin; Bleomycin; Vinblastine; Dacarbazine; Etoposide; Cyclophosphamide; Vincristine; Procarbazine; Prednisone

Harlachinger Krebshilfe e.V. - Recruiting 18 years to 75 years.
- A Prospective Multicenter Study on HIV-associated Hodgkin Lymphoma.
Doxorubicin; Bleomycin; Vinblastine; Dacarbazine; Etoposide; Cyclophosphamide; Vincristine; Procarbazine; Prednisone

Burkitt Lymphoma, or B-Cell Acute Lymphoblastic Leukemia Clinical Trial using Chemotherapy-Rituximab combination

Northern Italy Leukemia Group - Recruiting 15 years or older.
- Multicentre Study to Optimize Therapy of Burkitt's Leukemia (B-ALL) and Non-Hodgkin Lymphoma.
Chemotherapy-Rituximab combination

Fatigue, or Hodgkin Lymphoma Clinical Trial

Vanderbilt University - Recruiting 15 years to 39 years.
- .

Lymphoma Clinical Trial using cyclophosphamide; prednisolone; vinblastine sulfate; watchful waiting; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting N/A to 17 years.
- First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents.
cyclophosphamide; prednisolone; vinblastine sulfate; watchful waiting; therapeutic conventional surgery

Lymphoma Clinical Trial using bleomycin sulfate; cyclophosphamide; etoposide; mitoxantrone hydrochloride; prednisolone; procarbazine hydrochloride; vinblastine sulfate

National Cancer Institute (NCI) - Recruiting 60 years or older.
- A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ò 60 Years.
bleomycin sulfate; cyclophosphamide; etoposide; mitoxantrone hydrochloride; prednisolone; procarbazine hydrochloride; vinblastine sulfate

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, or Multiple Myeloma Clinical Trial using Total Body Irradiation; Fludarabine; Recipient Leukocyte Infusion

Massachusetts General Hospital - Recruiting 18 years to 74 years.
- Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation.
Total Body Irradiation; Fludarabine; Recipient Leukocyte Infusion

Lymphoma Clinical Trial using rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

National Cancer Institute (NCI) - Recruiting 18 years to 60 years.
- Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study].
rituximab; cyclophosphamide; doxorubicin hydrochloride; prednisone; vincristine sulfate

Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma Clinical Trial using Rituximab

University of Bologna - Recruiting 18 years or older.
- Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults.
Rituximab

No Hodgkin B Lymphoma Clinical Trial using RCOMP-14 + rituximab

Asociacion Doctor Peset Para el Estudio de la Hematolog¡a - Recruiting 18 years to 70 years.
- Phase II, Multicenter Trial to Evaluate the Efficacy and Safety of the Following Treatment Squeme:Ciclophosphamide, Vincristine, Lyposomal Doxorrubicine, Myocet and Prednisone,Combined With Rituximab in First Line Treatment for Patients With Aggresive No Hodgkin B Lymphoma and Cardiovascular Risk.
RCOMP-14 + rituximab

Non-Hodgkin's Lymphoma Clinical Trial using CHOEP + Rituximab; Mega-CHOEP + Rituximab

German High-Grade Non-Hodgkin's Lymphoma Study Group - Recruiting 18 years to 60 years.
- A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL.
CHOEP + Rituximab; Mega-CHOEP + Rituximab

Non-Hodgkin Lymphoma Clinical Trial using Ibritumomab Tiuxetan (Zevalin)

Grupo Espa¤ol de Linfomas y Transplante Aut¢logo de M‚dula Osea - Recruiting 18 years to 65 years.
- Allogeneic Transplantation of Haematopoietic Stem Cells Following Non-Myeloablative Conditioning With Melphalan, Fludarabine, Thiotepa, Rituximab and Ibritumomab Tiuxetan (Zevalin) in Patients With Aggressive Non-Hodgkin's B-Cell Lymphoma.
Ibritumomab Tiuxetan (Zevalin)

Non-Hodgkin's Lymphoma Clinical Trial using Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)

Grupo Espa¤ol de Linfomas y Transplante Aut¢logo de M‚dula Osea - Recruiting 18 years to 70 years.
- Autologous Transplantation of Haematopoietic Stem Cells With Conditioning Including Zevalin + BEAM to Patients Suffering From Refractory Large B-Cell Diffuse Lymphom.
Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)

Lymphoma, or Lymphoma, Non-Hodgkin Clinical Trial using proton pump inhibitor; clarithromycin; amoxicillin; metronidazole; radiation therapy

Technische Universit„t Dresden - Recruiting 18 years to 75 years.
- Treatment of Low-Grade Gastric Non-Hodgkin`s Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study).
proton pump inhibitor; clarithromycin; amoxicillin; metronidazole; radiation therapy

Non-Hodgkin Lymphoma Clinical Trial using Rituximab

Instituto Nacional de Cancerologia de Mexico - Recruiting 15 years to 60 years.
- Selection of Young Patients (< 61 Years), With Good Prognosis Diffuse Large B Cell Lymphoma, According to the Immunophenotype (BCL-6 Negative) to be Treated With Chemoimmunotherapy, With R-CHOP. A Pilot Study..
Rituximab